ABVC BioPharma ABV-1505 ADHD Phase IIa Results Presented At 2023 APSARD Conference
ABVC BioPharma, Inc. (NASDAQ:ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced that Dr. Keith McBurnett, Professor of